TIBER CREEK GROUP for AMGEN INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues related to capping out-of-pocket costs; Issues related to payments for ESRD services under Medicare; Issues related to Medicare Part D drug rebates; S. 1943 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| COREY MALMGREN | — |
Health Issues HCR
S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; Consolidated Appropriations Act, 2023 (PL 117-328), Division FF, Title III - Food and Drug Administration, Subtitle B - Drugs and Biologics and Subtitle F, Chapter 1 - Clinical Trial Diversity and Modernization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| COREY MALMGREN | — |
Budget/Appropriations BUD
Issues related to treatment challenges for cardiovascular disease.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHON JONES | — |
| MATTHEW LEFFINGWELL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.